Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

BRAF V600

20th Jun 2025

Exploring encorafenib and binimetinib dosing options for BRAF V600-mutant melanoma with brain metastases: Plain language summary of the POLARIS study

20th May 2025

A plain language summary: early STARBOARD study results for encorafenib, binimetinib and pembrolizumab in BRAF V600-mutant melanoma

23rd Jan 2025

A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma

Here, we summarize the 5-year results from part 1 of the COLUMBUS clinical study, which looked at the combination treatment of encorafenib plus binimetinib in people with a specific type of skin cancer called melanoma. Encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) are medicines used to treat a type of melanoma that has a change in the BRAF gene, called advanced or metastatic BRAF V600-mutant melanoma. Participants with advanced or metastatic BRAF V600-mutant melanoma took either encorafenib plus binimetinib together (COMBO group), compared with encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group).
20th Jun 2023

Encorafenib and binimetinib for people with BRAF V600-mutant melanoma, 5-year update of the COLUMBUS study- Plain Language Summary

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy